All of us at Sun Pharma are thinking of you and all the healthcare providers who are on the frontlines of patient care during this very difficult time.
COVID-19 Guidance From Professional Organizations
As the manufacturer of ILUMYA® (tildrakizumab-asmn), Sun Pharma fully supports the guidance of the American Academy of Dermatology (AAD), the International Psoriasis Council (IPC), and the National Psoriasis Foundation (NPF):
Medicare Provisions During COVID-19
As you probably know, the Centers for Medicare & Medicaid Services (CMS) has expanded Medicare provisions to ensure patient care and treatment continues during this unprecedented time—including payment for telehealth services for Medicare beneficiaries. For information on telehealth services and coding for your Medicare Part B patients, or to find alternate sites of care for ILUMYA® injections in your area, please refer to the links below:
ILUMYA® remains a covered benefit and is reimbursable under Medicare Part B, regardless of updates to the Self-Administered Drug (SAD) Exclusion List. For the most current information pertaining to the SAD list of biologics, click here.
ILUMYA® Resources and Links
Here are a few resources that may be of help to you as you consider starting or continuing your patients on ILUMYA®:
INDICATION AND IMPORTANT SAFETY INFORMATION
ILUMYA® (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy.
ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves.
Pretreatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment.
Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines.
The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.